TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4080
Drug: Metoprolol 20
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 20 mg t.d.s.
Study: 4080
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg t.d.s.
Study: 28242873
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (60 IU)
Study: 26493435
Drug: Moxifloxacin (MOX)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (MOX) therapy
Study: 20157016
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group
Study: 16984588
Drug: Preoperative proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative proton pump inhibitor (PPI) administration for 1 week before EMR
Study: 16984588
Drug: Endoscopic mucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic mucosal resection (EMR) without preoperative PPI administration
Study: 7037868
Drug: Zomepirac sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac sodium, 100 mg
Study: 7037868
Drug: Oxycodone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone with APC (Percodan)
Study: 28878181
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil supplement (control)
Study: 29287669
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to neoadjuvant carboplatin‐paclitaxel chemotherapy
Study: 30641618
Drug: Fangshuan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fangshuan Capsule (FC), 6 pills each time, three times per day for at least 2 days before PCI operation, therapeutic course of 2 weeks.
Study: 30641618
Drug: Fangshuan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fangshuan Capsule (FC)
Study: 18801111
Drug: 3.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/day maca
Study: 18801111
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day maca
Study: 18801111
Drug: Maca (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca (both doses)
Study: 16936236
Drug: Theophylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (400 mg/day orally)
Study: 16936236
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) (400 mug/day inhalation)
Study: 10939786
Drug: Perindopril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril treatment for blood pressure reduction
Study: 8967704
Drug: LDL apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL apheresis plus simvastatin, 40 mg/d
Study: 8967704
Drug: Simvastatin, 40
Normalized name: Simvastatin, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 40 mg/d
Study: 1548923
Drug: Heparin-coated equipment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated equipment with low systemic heparinization (heparin 5000 IU) during left heart bypass or partial cardiopulmonary bypass
Study: 3933102
Drug: Tocainide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (250 mg, single i.v. dose)
Study: 3933102
Drug: Lidocaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (100 mg, single i.v. dose)
Study: 28829923
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy intake (1500 mg calcium/day)
Study: 28829923
Drug: Low dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dairy intake (600 mg calcium/day)
Study: 26460572
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT; Coping cat program)
Study: 25500320
Drug: Pharmacotherapy (sertraline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (sertraline)
Study: 28278599
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and sertraline
Study: 12552048
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic applied on the contralateral forearm and foot
Study: 11071034
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg clonidine
Study: 30760204
Drug: Standard routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard routine pharmaceutical clinical care
Study: 22460966
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of valacyclovir twice daily for 1 year after initial treatment with 1 g of valacyclovir 3 times daily for 1 week
Study: 20228387
Drug: Treatment success
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment success
Study: 20228387
Drug: Dyspnoea relief
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyspnoea relief and treatment success
Study: 18005588
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (mean blood glucose 4.4 - 6.1 mmol/L)
Study: 18005588
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (mean blood glucose 6.7 - 8.3 mmol/L)
Study: 6355056
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir ointment
Study: 25929250
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment
Study: 29185897
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication with hypnotic effect (specific medications include mirtazapine and clotiapine)
Study: 29185897
Drug: Mirtazapine and
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine and clotiapine (hypnotic treatments)
Study: 22807523
Drug: RBV induction
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV induction (2000 mg/d) plus erythropoietin β (450 IU/kg/wk)
Study: 22807523
Drug: RBV standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBV standard dosing (1000 or 1200 mg/d)
Study: 22807523
Drug: RBV standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBV standard dosing
Study: 17933159
Drug: Myolaxin ointment
Normalized name: benzocaine / chloroxylenol / hydrocortisone acetate Otic Suspension [Myoxin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myolaxin ointment
Study: 7435798
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg orally once a week)
Study: 19967420
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 1,800 mg
Study: 19967420
Drug: Epigallocatechin gallate
Normalized name: Epigallocatechin Gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin gallate (EGCG) 1,800 mg
Study: 18008241
Drug: Standard 2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2-dose IPTp (sulfadoxine-pyrimethamine)
Study: 16247737
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg glycine sublingually
Study: 12219187
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol ester (PSE) treatment (2.8g/d = 1.68 phytosterols)
Study: 2254557
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no treatment)
Study: 30932133
Drug: RJ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RJ group (BCAA-enriched nutritional supplements, 2500 mg BCAA and 20 IU vitamin D, twice a day until hospital discharge)
Study: 29781649
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy augmented by a relational focus (CBT‐R)
Study: 27817813
Drug: Budesonide/formoterol Easyhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol Easyhaler (320/9 μg)
Study: 27817813
Drug: Budesonide/formoterol Easyhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol Easyhaler (1280/36 μg)
Study: 27817813
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbuhaler (320/9 μg)
Study: 27817813
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbuhaler (1280/36 μg)
Study: 31067538
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) treatment
Study: 760746
Drug: Intravenous propantheline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propantheline bromide (15 mg)
Study: 760746
Drug: Oral propantheline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propantheline bromide (15 mg)
Study: 30827722
Drug: Polyunsaturated fatty
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated fatty acids (PUFA) 3.6 g/d n-3 PUFA
Study: 24439830
Drug: Olanzapine+Sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine+Sertraline
Study: 21720264
Drug: Atenolol-based treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based treatment
Study: 22499288
Drug: Losartan and
Normalized name: losartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan and Atenolol-based treatment
Study: 16044063
Drug: office-based vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: office-based vision therapy/orthoptics
Study: 16044063
Drug: office-based placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: office-based placebo vision therapy/orthoptics
Study: 7751409
Drug: Amitriptyline (AMI)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AMI) and Fluoxetine (FLU) combination
Study: 31152309
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (NS) oil capsules (1350 mg/day)
Study: 18082737
Drug: Metformin tablets
Normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin tablets
Study: 28826745
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.5% ropivacaine for 96 hours
Study: 28826745
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion (normal saline) for 96 hours
Study: 25351453
Drug: Glutamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (10 g 3 times a day)
Study: 23988855
Drug: α-Lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Lipoic acid (ALA) treatment for 2 days (600 mg orally three times a day before and after coronary catheterization, n = 100)
Study: 21481742
Drug: Rufinamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide (up to 45 mg/kg daily) as adjunctive therapy
Study: 19686530
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with varenicline
Study: 15304151
Drug: ABMK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABMK treatment (Agaricus blazei Murill Kyowa)
Study: 8282361
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg given at 6 AM on awakening
Study: 8282361
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg given at 8:30 AM after breakfast
Study: 8282361
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg given at 6 PM after supper
Study: 31687205
Drug: No-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment
Study: 18682739
Drug: 8-week primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week primaquine (PQ) regimen (0.75 mg/kg/week)
Study: 18682739
Drug: 14-day primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day primaquine (PQ) regimen (0.5 mg/kg/day)
Study: 18682739
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once weekly 8-week)
Study: 10809915
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of botulinum toxin (Botox(R)) 2 U/4 cm2
Study: 9863158
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg.d‐1)
Study: 3523396
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 mg)
Study: 6125636
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medication)
Study: 27494089
Drug: Ofatumumab plus
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab plus chlorambucil (oral chlorambucil 10 mg/m2 on Days 1-7 of a 28-day cycle; ofatumumab: Cycle 1: 300 mg on Day 1 and 1000 mg on Day 8; subsequent cycles: 1000 mg Day 1 for 3-12 cycles)
Study: 27494089
Drug: Chlorambucil monotherapy
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil monotherapy (oral chlorambucil 10 mg/m2 on Days 1-7 of a 28-day cycle)
Study: 24120714
Drug: prednisolone 2.5
Normalized name: prednisolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 2.5 mg
Study: 24120714
Drug: prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 5 mg
Study: 24120714
Drug: prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 7.5 mg
Study: 24120714
Drug: prednisolone 10
Normalized name: prednisolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 10 mg
Study: 24120714
Drug: prednisolone 15
Normalized name: prednisolone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone 15 mg
Study: 17572346
Drug: Atropine 1%
Normalized name: Isopto Atropine 1% Ophthalmic Solution
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine 1% solution (N = 134)
Study: 14747205
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance and beta-cell function
Study: 7578765
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg IV every 8 hours
Study: 7578765
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg IV every 6 hours
Study: 1101611
Drug: Etidocaine 1%
Normalized name: etidocaine 1% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidocaine 1% with adrenaline 5 mug/ml
Study: 1101611
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with adrenaline 5 mug/ml
Study: 31062079
Drug: Tea catechin-enriched
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tea catechin-enriched beverage (611 mg catechins, 88 mg caffeine)
Study: 31062079
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (0 mg catechins, 81 mg caffeine)
Study: 29364091
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) monotherapy
Study: 30662324
Drug: LAM and
Normalized name: Alprazolam and propranolol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM and ADV combination therapy (Control)
Study: 20570319
Drug: Nitrofurantoin (NFT)
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin (NFT) prophylaxis 100 mg b.i.d. for 7 days preoperatively
Study: 20570319
Drug: Standard perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard perioperative antibiotic prophylaxis
Study: 16476929
Drug: DCA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCA (25 mg/kg/day)
Study: 9279344
Drug: TUT-7 (menogaril)
Normalized name: favor tutti frutti
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUT-7 (menogaril) at 75 or 100 mg/body/day for 7 or 14 days with two-week drug withdrawal
Study: 8443037
Drug: MDL 72394
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72394 (MAO‐A inhibitor) 16 mg
Study: 8443037
Drug: MDL 72974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72974A (MAO‐B inhibitor) 12 mg
Study: 27793175
Drug: Luminor® paclitaxel‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luminor® paclitaxel‐coated drug‐eluting balloon (DEB) catheter
Study: 24322377
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus S-1 (GS) combination chemotherapy
Study: 22283861
Drug: T lymphocytes
Normalized name: Autologous Activated T Lymphocytes (ATL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR) in late responders (LR)
Study: 22283861
Drug: T lymphocytes
Normalized name: Autologous Activated T Lymphocytes (ATL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR) in early responders (ER)
Study: 22283861
Drug: T lymphocytes
Normalized name: Autologous Activated T Lymphocytes (ATL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR)
Study: 20334686
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss intervention (diet, physical activity, behavioral therapy)
Study: 21910821
Drug: Enoxaparin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.5 mg/kg body weight)
Study: 18674465
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5,000 units)
Study: 12134175
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months antiepileptic drug therapy
Study: 12134175
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years antiepileptic drug therapy
Study: 7995773
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant interferon gamma (r IFN-gamma) at doses of 0.1, 0.2, 0.6, 1.8, or 5.4 mg
Study: 7995773
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant interferon gamma (r IFN-gamma)
Study: 2186320
Drug: Doxorubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (40 mg/m2) + Cyclophosphamide (600 mg/m2)
Study: 2186320
Drug: Epirubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (40 mg/m2) + Cyclophosphamide (600 mg/m2)
Study: 2186320
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg/m2) + Cyclophosphamide (600 mg/m2)
Study: 2186320
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who had previously received adjuvant chemotherapy
Study: 406624
Drug: Marijuana low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana low dose with aversive noise
Study: 406624
Drug: Marijuana low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana low dose without aversive noise
Study: 406624
Drug: Marijuana high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana high dose with aversive noise
Study: 406624
Drug: Marijuana high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana high dose without aversive noise
Study: 28528567
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) consisting of 12 individual sessions with a psychologist over 16 weeks
Study: 28528567
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment consisting of three consultations with an MS nurse over 16 weeks
Study: 19757514
Drug: 2 l
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l polyethylene glycol (group A)
Study: 19757514
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l polyethylene glycol (group B)
Study: 20661545
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/day
Study: 1653140
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg sumatriptan
Study: 31872245
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily of icosapent ethyl
Study: 31872245
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (control)
Study: 10574619
Drug: rHuIL-10 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL-10 at a dose of 4 or 8 microg/kg/day as a single daily subcutaneous injection for 28 days
Study: 9064111
Drug: Orocal 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orocal 500 mg (one dissolve-in-the-mouth tablet in the morning and one in the evening)
Study: 9064111
Drug: Cacit 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cacit 1000 (one effervescent tablet)
Study: 9064111
Drug: Orocal 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orocal 500 mg (two tablets in a single dose)
Study: 9064111
Drug: Orocal 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orocal 500 mg (two doses)
Study: 6847466
Drug: Mild silver
Normalized name: mild silver protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild silver protein solution (Argyrol)
Study: 26347970
Drug: 4-hour transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour transcutaneous tibial nerve stimulation for 6 weeks (total of 12 treatments)
Study: 24247188
Drug: Pycnogenol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol 100 mg/day